Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Finished Goods (2023 - 2025)

Krystal Biotech's Finished Goods history spans 3 years, with the latest figure at $9.3 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 338.05% year-over-year to $9.3 million; the TTM value through Dec 2025 reached $9.3 million, up 338.05%, while the annual FY2025 figure was $9.3 million, 338.05% up from the prior year.
  • Finished Goods for Q4 2025 was $9.3 million at Krystal Biotech, up from $7.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $9.3 million in Q4 2025 and bottomed at $161000.0 in Q1 2024.
  • The 3-year median for Finished Goods is $2.1 million (2024), against an average of $3.5 million.
  • The largest YoY upside for Finished Goods was 3563.35% in 2025 against a maximum downside of 4.03% in 2025.
  • A 3-year view of Finished Goods shows it stood at $627000.0 in 2023, then skyrocketed by 239.07% to $2.1 million in 2024, then surged by 338.05% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Finished Goods are $9.3 million (Q4 2025), $7.3 million (Q3 2025), and $1.7 million (Q2 2025).